Drug Profile
SPC 5001
Alternative Names: SPC-5001Latest Information Update: 04 Dec 2014
Price :
$50
*
At a glance
- Originator Santaris Pharma
- Developer Roche
- Class Antihyperlipidaemics; Antisense oligonucleotides
- Mechanism of Action Antisense RNA inhibitors; PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 04 May 2011 Phase-I clinical trials in familial Hypercholesterolaemia in the Netherlands (SC)
- 04 May 2011 Phase-I clinical trials in Hypercholesterolaemia (in volunteers) in the Netherlands (SC)